Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $18.13 Average Target Price from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $18.13.

ATEC has been the subject of several recent analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a research note on Monday, June 16th. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Finally, Piper Sandler reissued an "overweight" rating and set a $15.00 price target (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd.

Insider Activity

In related news, Director Karen K. Mcginnis sold 3,963 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $12.11, for a total value of $47,991.93. Following the sale, the director owned 68,709 shares in the company, valued at approximately $832,065.99. The trade was a 5.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Craig E. Hunsaker sold 13,878 shares of the business's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $12.36, for a total transaction of $171,532.08. Following the transaction, the executive vice president owned 1,450,018 shares in the company, valued at $17,922,222.48. This trade represents a 0.95% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 299,547 shares of company stock valued at $3,698,956 in the last 90 days. 20.90% of the stock is currently owned by insiders.

Institutional Trading of Alphatec

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC increased its holdings in shares of Alphatec by 38,433.3% during the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock valued at $228,000 after acquiring an additional 2,306 shares in the last quarter. Comerica Bank lifted its position in shares of Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after buying an additional 1,248 shares in the last quarter. Larson Financial Group LLC purchased a new position in shares of Alphatec during the 1st quarter valued at approximately $54,000. Quarry LP lifted its holdings in Alphatec by 79.2% in the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after purchasing an additional 2,375 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Alphatec in the 4th quarter valued at $76,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Stock Down 1.3%

ATEC traded down $0.14 during trading on Thursday, hitting $10.49. The company had a trading volume of 1,180,868 shares, compared to its average volume of 1,926,878. The company has a market capitalization of $1.53 billion, a PE ratio of -9.12 and a beta of 1.05. Alphatec has a one year low of $4.88 and a one year high of $13.14. The firm's 50-day moving average price is $11.74 and its 200 day moving average price is $11.06.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The firm had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The firm's revenue for the quarter was up 22.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. Sell-side analysts forecast that Alphatec will post -1.08 earnings per share for the current year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.